Arabic Arabic English English French French German German
dark

Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne

Ascletis Pharma Inc. announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board

Next Post

UNIST Partners with Yonsei University Health System to Empower Smart Healthcare

Related Posts
Total
0
Share